

## PCV

### INDICATION (ICD10) C71, C72

1. Oligodendroglioma (grade 2 or 3) adjuvant following radiotherapy and / or relapse after first line treatment.
2. Astrocytoma grade 2 adjuvant following radiotherapy.  
PS 0, 1, 2

### REGIMEN

Day 1 LOMUSTINE (CCNU) 100mg/m<sup>2</sup> (maximum 200mg) orally single dose only  
VINCRIStINE 1.5mg/m<sup>2</sup> (maximum 2mg) in 50ml sodium chloride 0.9% IV infusion over 10 minutes  
Days 1 to 10 PROCARBAZINE 100mg/m<sup>2</sup>/day (maximum 200mg/day) orally in 3 divided doses

### CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 42 days for up to 6 cycles

### ADMINISTRATION

Lomustine  
Available as 40mg capsules  
Take at night on an empty stomach

Procarbazine  
Available as 50mg capsules  
With or without food

### ANTI-EMETICS

Moderate risk day 1 (take before lomustine dose)  
Patients may already be taking dexamethasone for raised intracranial pressure  
Low emetogenic risk days 2 to 10

### CONCURRENT MEDICATION REQUIRED

Lomustine	Lorazepam 1mg single dose may be helpful
-----------	------------------------------------------

### EXTRAVASATION AND TYPE OF LINE / FILTERS

Vincristine - vesicant

No filter  
Peripheral line

### INVESTIGATIONS

Blood results required before SACT administration  
FBC, U&E and LFTs every cycle  
Neutrophils x 10<sup>9</sup>/L ≥1.5  
Platelets x 10<sup>9</sup>/L ≥100  
Serum creatinine every cycle  
Baseline weight and every cycle

### MAIN TOXICITIES AND ADVERSE REACTIONS

Lomustine	Myelosuppression
Procarbazine	Rash – allergic can be severe, often occurs after cycles 2 or 3
Vincristine	Neuropathy

## INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS (not exhaustive list check SPC/BNF/Stockleys)

Procarbazine	Avoid weak MAO inhibitors, alcohol, narcotic analgesics, drugs with anticholinergic effects (including phenothiazine derivatives and tricyclic antidepressants), other CNS depressants and antihypertensive agents. High tyramine containing foods.
--------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## DOSE MODIFICATIONS

### Haematological

If neutrophils  $<1.5 \times 10^9/L$  and / or platelets  $<100 \times 10^9/L$ , delay 1 week or until count recovered then restart at 75% dose, then at 50% dose with further myelosuppression, dose can be reduced further to 25% dose.

### Non-haematological

Procarbazine

Rash stop procarbazine – do not restart.

Vincristine

Significant neuropathy omit vincristine.

### Hepatic impairment

Procarbazine

Bilirubin $>50 \mu\text{mol/L}$	consider giving 50%
Bilirubin $>85 \mu\text{mol/L}$ or AST $>180 \text{iu}$	omit

Vincristine

Bilirubin 25-51 or AST 60-180u/L	give 50%
Bilirubin $>51 \mu\text{mol/L}$ and normal AST	give 50%
Bilirubin $>51 \mu\text{mol/L}$ and AST $>180 \text{u/L}$	omit

### Renal impairment

Lomustine

CrCl $>60 \text{ml/min}$	give 100%
CrCl 45-60ml/min	give 75%
CrCl 30-45ml/min	give 50%
CrCl $<30 \text{ml/min}$	Not recommended

Procarbazine

Serum creatinine $>120 \mu\text{mol/L}$	Discuss
Serum creatinine $>177 \mu\text{mol/L}$	give 50%
severe renal impairment	not recommended

## REFERENCES

1. Thomas D et al. J Clin Oncol 2001; 19: 509 518
2. Cairncross et al. 2013 RTOG 9402 trial